07:00 , May 12, 2014 |  BioCentury  |  Emerging Company Profile

Pharmasum: Down with AD

Pharmasum Therapeutics A/S is looking to treat the large number of Down syndrome patients who develop Alzheimer's disease-like pathology. The company's first-in-class inhibitor could slow cognitive decline in Down syndrome by targeting a kinase that...
08:00 , Jan 21, 2013 |  BC Week In Review  |  Clinical News

Proteome Sciences preclinical data

In a mouse model of AD, PS110 improved cognitive function as assessed by the Morris Water Maze test vs. vehicle-treated controls. Proteome said next steps include pharmacokinetic testing of the casein kinase 1 delta (...
08:00 , Jan 21, 2013 |  BC Week In Review  |  Clinical News

Proteome Sciences preclinical data

In a mouse model of AD, PS278-05 improved cognitive function as assessed by the Morris Water Maze test vs. vehicle-treated controls. Proteome said next steps include pharmacokinetic testing of the casein kinase 1 delta (...
07:00 , Oct 20, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Various

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Insomnia; diabetes; cardiovascular disease Casein kinase 1d (CSNK1D; CKI-d) A small molecule inhibitor of CKI-d that prolongs circadian rhythms could help...
07:00 , Aug 30, 2010 |  BC Week In Review  |  Clinical News

Pfizer preclinical data

Researchers at the University of Manchester and colleagues reported that once-daily PF-670462 produced "robust" 24-hour activity cycles that persisted throughout treatment in mice rendered behaviorally arrhythmic. PF-670462 is a casein kinase 1 delta ( CSNK1D...